

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 11 2001

TECH CENTER 1600/2900

In re Patent Application of

GLENN et al.

Appln. No. 09/266,803

Filed: March 12, 1999

FOR: ADP-RIBOSYLATING EXOTOXIN USED FOR TRANSCUTANEOUS IMMUNIZATION (as amended)



Group Art Unit: 1644

Examiner: M. Tung

15/A
KD
6-16-01

* * * *

June 7, 2001

AMENDMENT UNDER 37 CFR § 1.111

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the pending Office Action mailed December 7, 2001 (Paper No. 14), entry and consideration of the following amendments and remarks are respectfully requested.

IN THE TITLE:

Kindly delete the title and replace it with the following new title.

ADP-RIBOSYLATING EXOTOXIN USED FOR TRANSCUTANEOUS IMMUNIZATION

IN THE CLAIMS:

Kindly enter the following amended claims.

1. (Amended) A method of inducing an immune response comprising:

- (a) applying a formulation to intact skin of an organism, wherein the formulation comprises an antigen and an ADP-ribosylating exotoxin;
- (b) activating a Langerhans cell with the ADP-ribosylating exotoxin; and
- (c) presenting the antigen on a cell surface of the Langerhans cell to a lymphocyte, thereby inducing the immune response in the organism.

06/11/2001 BNGUYEN1 00000016 033975 09266803

01 FC:117 890.00 CH

30186858v1

06/11/2001 BNGUYEN1 00000016 033975 09266803

02 FC:126 180.00 CH

Sub B2
A1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): GLENN et al.

Appln. No.: 09

266,803

Series Code ↑

Serial No. ↑

Filed: March 12, 1999

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Art Unit 1644

Examiner: M. Tung

Atty. Dkt. P 0256865

1001CIP1DIV1

Appln. Title: ADP-RIBOSYLATING EXOTOXIN
USED FOR TRANSCUTANEOUS
IMMUNIZATION (as amended)

Sir:

AMENDMENT

Date: June 7, 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim		Claims remaining after amendment		Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm	
A. <input checked="" type="checkbox"/> NOT made	For B & C See Required Separate Paper (Pat-256)	B. <input type="checkbox"/> Withdrawn							
C. <input type="checkbox"/> made herewith									
D. <input type="checkbox"/> made previously									
2. Total Effective Claims		40	**minus	40	0	x \$18/\$9 =	+ \$0	103/203	
3. Independent Claims		6	***minus	6	0	x \$80/\$40 =	+ \$0	102/202	
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)							+ \$270/\$135 =	+ \$0	104/204
5. Original due Date: December 7, 2001		<input type="checkbox"/> NONE							
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo)	\$110/\$55 =					115/215	
		(2 mos)	\$390/\$195 =			+ \$890		116/216	
		(3 mos)	\$890/\$445 =					117/217	
		(Usable only for ≤ 2mo.OA --- 4 mos)	\$1390/\$695=					118/218	
		(Usable only for 30 day/1mo.OA --- 5 mos)	\$1890/\$945=					128/228	
7. Enter any previous extension fee paid since above original due date and subtract						- \$0			
8. Extension Fee Attached						+ \$890			
9. If Terminal Disclaimer attached, add Rule 20(d) official fee						+ \$110/\$55	+ \$0	148/248	
10. If IDS attached requires Official Fee under Rule 97 (c),						+ \$180	+ \$180	126	
or if Rule 97(d) Request						+ \$180		126	
11. After-Final Request Fee per rules 129(a) and 17(r)						+ \$710/355	+ \$0	146/246	
12. No. of additional inventions for examination per Rule 129(b).....						x \$710/355 ea	+ \$0	149/249	
13. Request for Continued Examination (RCE)						+ \$710/355	+ \$0	1179/1279	
14. Petition fee for						+ \$0			

15.

CHARGE DEPOSIT ACCOUNT

\$1070 RECEIVED

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 081255 0256865
C# M#

JUN 11 2001

TECH CENTER 1600/25

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

For Atty: Paul N. Kokulis

Sig: *Kary J. Jurgens* 43180

Reg. No. 16773

Fax: (202) 822-0944

Tel: (202) 861-3503

1100 New York Avenue, NW
Washington, DC 20005-3918

Tel: (202) 861-3000

Atty/Sec: PNK/GRT

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments